

Ref: FOI/CAD/ID 3372

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

21 June 2016

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to testing services for cancer indications and therapies.

Do you currently offer a companion diagnostic (stratified medicine) testing services for the following cancer indications and therapies? If so I would be grateful if you could please indicate which tests are offered, the charge per patient test (ideally a comment on what the overhead/kit breakdown of the test cost) and the number performed per year January-December (or month if easier – please specify in comments). The brand name of the test used or any information regarding commercial partnerships would also be appreciated to be included in the comments.

Test Types: IHC = Immunohistochemistry, FISH = Fluorescent In-Situ Hybridization, PCR = Polymerase Chain Reaction, Pyro= Pyrosequencing, NGS = Next Generation Sequencing. If the lab performs another test type or the test is linked to another oncological therapy not listed please check "Other" and include it in the comments section.

Please see the completed form:

** The Pathology Service is currently undergoing a tendering process and the information requested is exempt from disclosure under the Freedom of Information Act 2000 Section 43 as its disclosure would, or would be likely to, prejudice the commercial interests of any person (including the public authority holding it).

Indication	Marker	Test type	Charge per patient	Number of test per year	How many tests were used for the following	Comments
Breast Cancer	HER2	<input checked="" type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014: 2441	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	Unknown indications. Do not collect this data Ventana 4B5 antibody (Roche Tissue diagnostics)
				2015: 2523	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
		<input type="checkbox"/> IHC <input checked="" type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014: 506	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	Unknown indications. Do not collect this data Pathvysion FISH kit (Abbott Molecular)
				2015: 576	<input type="checkbox"/> Trastuzumab (Herceptin) <input type="checkbox"/> Pertuzumab <input type="checkbox"/> Ado-trastuzumab	
Colorectal Cancer	KRAS	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input checked="" type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014: 219	<input type="checkbox"/> Cetuximab <input type="checkbox"/> Panitumumab	Unknown indications. Do not collect this data Cobas KRAS kit (Roche Molecular) Partially outsourced during 2015
				2015: 221	<input type="checkbox"/> Cetuximab <input type="checkbox"/> Panitumumab	
Non-Small Cell Lung Cancer	EGFR	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014: 228	<input type="checkbox"/> Afatinib <input type="checkbox"/> Erlotinib <input type="checkbox"/> Gefitinib <input type="checkbox"/> Osimertinib	Unknown indications. Do not collect this data EGFR testing Outsourced
				2015: 235	<input type="checkbox"/> Afatinib <input type="checkbox"/> Erlotinib <input type="checkbox"/> Gefitinib <input type="checkbox"/> Osimertinib	
	ALK	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS	**	2014: 228	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	Unknown indications. Do not collect this data ALK testing outsourced
				2015:	<input type="checkbox"/> Crizotinib	

		<input type="checkbox"/> Other		70	<input type="checkbox"/> Other	
		<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input type="checkbox"/> PCR <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other	
			2015:	<input type="checkbox"/> Crizotinib <input type="checkbox"/> Other		
Melanoma	BRAF	<input type="checkbox"/> IHC <input type="checkbox"/> FISH <input checked="" type="checkbox"/> PCR <input type="checkbox"/> Pyro <input type="checkbox"/> NGS <input type="checkbox"/> Other	**	2014: 71	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	Unknown indications. Do not collect this data Tests outsourced in time period specified Cobas BRAF Kit (Roche Molecular)
				2015 91	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	
				2015:	<input type="checkbox"/> Dabrafenib <input type="checkbox"/> Vemurafenib <input type="checkbox"/> Trametinib	